- Home
- Automated
- NDF A-Z listing
- Tremelimumab
T
Tremelimumab
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
Yes
Summary of Biologics
No
Active ingredient: Tremelimumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended durvalumab in combination with tremelimumab for inclusion on the MOH List of Subsidised Drugs for treating unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy. The decision for durvalumab in combination with tremelimumab was based on its unfavourable cost effectiveness versus sorafenib, its uncertain clinical and cost effectiveness versus atezolizumab plus bevacizumab, and the unacceptable price-volume agreements proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for durvalumab plus tremelimumab are provided in the Annex.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |